Sera Prognostics Stock Earnings Reports

Sera Prognostics is transitioning from a clinical-stage to a commercialization-focused company following publication of the PRIME trial. Management concentrated Q1 efforts on clinician and stakeholder education (medical meetings, podcasts, targeted media) and expanding access via partnership programs — three live programs now with a cadence of roughly one new partner program per quarter. The company is engaging 13 payers across 15 states and pursuing payer- and state-level advocacy (including a provider letter-writing campaign) to drive Medicaid and value‑based coverage. European commercialization preparations continue with a midyear CE Mark submission planned and multiple publications pending (including health economics and Medicaid subgroup analyses). Management realigned operations to prioritize commercialization, market access and medical engagement while reducing R&D/ClinOps footprint; they expect ~ $10 million in annualized operating expense savings, extending cash runway through 2029. Financially, Q1 revenue was minimal ($14k), operating expenses were $9.4M, net loss was $8.4M, and cash and equivalents totaled $86.8M. Management cautions 2026 revenue may remain modest and lumpy as payers and programs transition from setup to implementation, with more meaningful pull‑through expected late 2026 into 2027.